Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease
Clinical Infectious Diseases · 05.10.2023 · 77 (7) · 1053-1062
DOI: 10.1093/cid/ciad312 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 30.05.2023. Verfasst von Connie A Haley und 53 weiteren Autor:innen. Beteiligte Einrichtung: Southeastern National Tuberculosis Center, Division of Infectious Diseases and Global Medicine, Department of Medicine in the College of Medicine, Un…. Hauptthemen laut MEDLINE: Tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS, NIAID NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
Background
Rifampin-resistant tuberculosis is a leading cause of morbidity worldwide; only one-third of persons start treatment, and outcomes are often inadequate. Several trials demonstrate 90% efficacy using an all-oral, 6-month regimen of bedaquiline, pretomanid, and linezolid (BPaL), but significant toxicity occurred using 1200-mg linezolid. After US Food and Drug Administration approval in 2019, some US clinicians rapidly implemented BPaL using an initial 600-mg linezolid dose adjusted by serum drug concentrations and clinical monitoring.
Methods
Data from US patients treated with BPaL between 14 October 2019 and 30 April 2022 were compiled and analyzed by the BPaL Implementation Group (BIG), including baseline examination and laboratory, electrocardiographic, and clinical monitoring throughout treatment and follow-up. Linezolid dosing and clinical management was provider driven, and most patients had linezolid adjusted by therapeutic drug monitoring.
Results
Of 70 patients starting BPaL, 2 changed to rifampin-based therapy, 68 (97.1%) completed BPaL, and 2 of the 68 (2.9%) experienced relapse after completion. Using an initial 600-mg linezolid dose daily adjusted by therapeutic drug monitoring and careful clinical and laboratory monitoring for adverse effects, supportive care, and expert consultation throughout BPaL treatment, 3 patients (4.4%) with hematologic toxicity and 4 (5.9%) with neurotoxicity required a change in linezolid dose or frequency. The median BPaL duration was 6 months.
Conclusions
BPaL has transformed treatment for rifampin-resistant or intolerant tuberculosis. In this cohort, effective treatment required less than half the duration recommended in 2019 US guidelines for drug-resistant tuberculosis. Use of individualized linezolid dosing and monitoring likely enhanced safety and treatment completion. The BIG cohort demonstrates that early implementation of new tuberculosis treatments in the United States is feasible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Southeastern National Tuberculosis Center, Division of Infectious Diseases and Global Medicine, Department of Medicine in the College of Medicine, University of Florida, Gainesville, Florida, USA.
- Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
- Georgia State Tuberculosis Program, Atlanta, Georgia, USA.
- Translational Research, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Förderung
- Intramural CDC HHS
- NIAID NIH HHS
- NIMHD NIH HHS
- NIH
Zitieren
APA
Haley, C. A., Schechter, M. C., Ashkin, D., Peloquin, C. A., Peter Cegielski, J., Andrino, B. B., Burgos, M., Caloia, L. A., Chen, L., Colon-Semidey, A., DeSilva, M. B., Dhanireddy, S., Dorman, S. E., Dworkin, F. F., Hammond-Epstein, H., Easton, A. V., Gaensbauer, J. T., Ghassemieh, B., Gomez, M. E., …, & BPaL Implementation Group (2023). Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease. Clinical Infectious Diseases, 77(7), 1053-1062. https://doi.org/10.1093/cid/ciad312
Vancouver
Haley CA, Schechter MC, Ashkin D, Peloquin CA, Peter Cegielski J, Andrino BB, et al. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease. Clinical Infectious Diseases. 2023;77(7):1053-1062. doi:10.1093/cid/ciad312
BibTeX
@article{Haley2023,
author = {Haley, Connie A and Schechter, Marcos C and Ashkin, David and Peloquin, Charles A and Peter Cegielski, J and Andrino, Barbara B and Burgos, Marcos and Caloia, Lori A and Chen, Lisa and Colon-Semidey, Angel and DeSilva, Malini B and Dhanireddy, Shireesha and Dorman, Susan E and Dworkin, Felicia F and Hammond-Epstein, Heidi and Easton, Alice V and Gaensbauer, James T and Ghassemieh, Bijan and Gomez, Maria E and Horne, David and Jasuja, Supriya and Jones, Betsy A and Kaplan, Leonard J and Khan, Asharaf Edward and Kracen, Elizabeth and Labuda, Sarah and Landers, Karen M and Lardizabal, Alfred A and Lasley, Maria T and Letzer, David M and Lopes, Vinicius K and Lubelchek, Ronald J and Patricia Macias, C and Mihalyov, Aimee and Misch, Elizabeth Ann and Murray, Jason A and Narita, Masahiro and Nilsen, Diana M and Ninneman, Megan J and Ogawa, Lynne and Oladele, Alawode and Overman, Melissa and Ray, Susan M and Ritger, Kathleen A and Rowlinson, Marie-Claire and Sabuwala, Nadya and Schiller, Thomas M and Schwartz, Lawrence E and Spitters, Christopher and Thomson, Douglas B and Tresgallo, Rene Rico and Valois, Patrick and Goswami, Neela D and BPaL Implementation Group, BPaL Implementation Group},
title = {Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {77},
number = {7},
pages = {1053--1062},
doi = {10.1093/cid/ciad312}
}
EUVIMED